Commentary
The identification of high-risk MAFLD patients is paramount. Liver biopsy is still considered the gold standard for the assessment of patients with MAFLD. The search for noninvasive biomarkers for MAFLD remains an area of intensive research.
In this review, J. Alharthi et al. (Westmead Hospital and University of Sydney, Australia, and Faculty of Science, Taif University, Saudi Arabia) provide an update on the current and future biomarkers of MAFLD
